Clinicopathologic study and outcome analysis of thyroid lymphomas: Experience from a tertiary cancer center
Background The aim of this study was to review clinicopathologic presentations of patients diagnosed with thyroid lymphomas at a tertiary cancer center. Thyroid lymphomas represent less than 2% of all lymphomas. Methods The lymphoma clinic database was retrospectively reviewed to collect information...
Gespeichert in:
| Veröffentlicht in: | Head & neck 2013-02, Vol.35 (2), p.165-171 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 171 |
|---|---|
| container_issue | 2 |
| container_start_page | 165 |
| container_title | Head & neck |
| container_volume | 35 |
| creator | Katna, Rakesh Shet, Tanuja Sengar, Manju Menon, Hari Laskar, Siddharth Prabhash, Kumar D'Cruz, Anil Nair, Reena |
| description | Background
The aim of this study was to review clinicopathologic presentations of patients diagnosed with thyroid lymphomas at a tertiary cancer center. Thyroid lymphomas represent less than 2% of all lymphomas.
Methods
The lymphoma clinic database was retrospectively reviewed to collect information on patients diagnosed with thyroid lymphomas. Tissue microarrays were constructed in 37 patients for evaluation of germinal center (CD10/bcl‐6) and activated B‐cell immunophenotype markers (FoxP1, Mum1).
Results
During 2000 to 2010, 64 of 5668 patients registered at our lymphoma clinic were diagnosed with thyroid lymphoma (1.7%). Complete response (CR) to treatment was seen in 80.7%. The germinal center immunophenotype and activated B‐cell immune phenotype did not influence the prognosis. FoxP1, however, was associated with poor treatment response and decreased survival.
Conclusions
Advanced International Prognostic Index (IPI) score and combined‐modality treatment emerged as significant prognostic factors for treatment response and overall survival. Immunophenotype expression of FoxP1 carries a poor prognosis in diffuse large B‐cell lymphoma as elsewhere. © 2012 Wiley Periodicals, Inc. Head Neck, 2013 |
| doi_str_mv | 10.1002/hed.22928 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1273800148</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1273800148</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3918-c5911f8d55eb0d79fbd98950ff7aafecf84b72210f8fc926da8a352ea06f28b23</originalsourceid><addsrcrecordid>eNp1kUtv1DAUhS0EoqWw4A8gS2xgkdaPJLbZwXQ6BcpjAWJpOc414zaJg52ozb-v2-mwQGJ1j46-e6R7D0IvKTmmhLCTLbTHjCkmH6FDSpQoCC_F4ztd8oITUR6gZyldEkJ4XbKn6IAxXkta1YfoatX5wdswmmkbuvDbW5ymuV2wGVoc5smGHrI23ZJ8wsHhabvE4FvcLf24Db1J7_D6ZoToYbCAXQw9NniCOHkTF2xNdiO2MGTrOXriTJfgxcM8Qj_P1j9W58XFt83H1fuLwnJFZWErRamTbVVBQ1qhXNMqqSrinDDGgXWybARjlDjprGJ1a6ThFQNDasdkw_gRerPLHWP4M0OadO-Tha4zA4Q5acoEl4TQUmb09T_oZZhjPveeooqXFVeZerujbAwpRXB6jL7P92lK9F0DOjeg7xvI7KuHxLnps7sn9y_PwMkOuPYdLP9P0ufr031ksdvwaYKbvxsmXulacFHpX183-sun7x9OV2cb_ZnfAkrQoDM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1271934539</pqid></control><display><type>article</type><title>Clinicopathologic study and outcome analysis of thyroid lymphomas: Experience from a tertiary cancer center</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Katna, Rakesh ; Shet, Tanuja ; Sengar, Manju ; Menon, Hari ; Laskar, Siddharth ; Prabhash, Kumar ; D'Cruz, Anil ; Nair, Reena</creator><creatorcontrib>Katna, Rakesh ; Shet, Tanuja ; Sengar, Manju ; Menon, Hari ; Laskar, Siddharth ; Prabhash, Kumar ; D'Cruz, Anil ; Nair, Reena</creatorcontrib><description>Background
The aim of this study was to review clinicopathologic presentations of patients diagnosed with thyroid lymphomas at a tertiary cancer center. Thyroid lymphomas represent less than 2% of all lymphomas.
Methods
The lymphoma clinic database was retrospectively reviewed to collect information on patients diagnosed with thyroid lymphomas. Tissue microarrays were constructed in 37 patients for evaluation of germinal center (CD10/bcl‐6) and activated B‐cell immunophenotype markers (FoxP1, Mum1).
Results
During 2000 to 2010, 64 of 5668 patients registered at our lymphoma clinic were diagnosed with thyroid lymphoma (1.7%). Complete response (CR) to treatment was seen in 80.7%. The germinal center immunophenotype and activated B‐cell immune phenotype did not influence the prognosis. FoxP1, however, was associated with poor treatment response and decreased survival.
Conclusions
Advanced International Prognostic Index (IPI) score and combined‐modality treatment emerged as significant prognostic factors for treatment response and overall survival. Immunophenotype expression of FoxP1 carries a poor prognosis in diffuse large B‐cell lymphoma as elsewhere. © 2012 Wiley Periodicals, Inc. Head Neck, 2013</description><identifier>ISSN: 1043-3074</identifier><identifier>EISSN: 1097-0347</identifier><identifier>DOI: 10.1002/hed.22928</identifier><identifier>PMID: 22368156</identifier><identifier>CODEN: HEANEE</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>activated B-cell lymphoma ; Adult ; Age Factors ; Aged ; Biopsy, Fine-Needle ; Chemoradiotherapy - methods ; Databases, Factual ; diffuse large B-cell lymphoma ; Disease-Free Survival ; extranodal lymphoma ; Female ; Forkhead Transcription Factors - genetics ; Gene Expression Regulation, Neoplastic ; germinal center B cell ; Humans ; Immunohistochemistry ; International Prognostic Index ; Kaplan-Meier Estimate ; Lymphoma, Large B-Cell, Diffuse - genetics ; Lymphoma, Large B-Cell, Diffuse - mortality ; Lymphoma, Large B-Cell, Diffuse - pathology ; Lymphoma, Large B-Cell, Diffuse - therapy ; Male ; Middle Aged ; Neoplasm Staging ; Prognosis ; Repressor Proteins - genetics ; Retrospective Studies ; Risk Assessment ; Sex Factors ; Survival Analysis ; Tertiary Care Centers ; Thyroid Neoplasms - genetics ; Thyroid Neoplasms - mortality ; Thyroid Neoplasms - pathology ; Thyroid Neoplasms - therapy ; tissue microarray</subject><ispartof>Head & neck, 2013-02, Vol.35 (2), p.165-171</ispartof><rights>Copyright © 2012 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3918-c5911f8d55eb0d79fbd98950ff7aafecf84b72210f8fc926da8a352ea06f28b23</citedby><cites>FETCH-LOGICAL-c3918-c5911f8d55eb0d79fbd98950ff7aafecf84b72210f8fc926da8a352ea06f28b23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhed.22928$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhed.22928$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22368156$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Katna, Rakesh</creatorcontrib><creatorcontrib>Shet, Tanuja</creatorcontrib><creatorcontrib>Sengar, Manju</creatorcontrib><creatorcontrib>Menon, Hari</creatorcontrib><creatorcontrib>Laskar, Siddharth</creatorcontrib><creatorcontrib>Prabhash, Kumar</creatorcontrib><creatorcontrib>D'Cruz, Anil</creatorcontrib><creatorcontrib>Nair, Reena</creatorcontrib><title>Clinicopathologic study and outcome analysis of thyroid lymphomas: Experience from a tertiary cancer center</title><title>Head & neck</title><addtitle>Head Neck</addtitle><description>Background
The aim of this study was to review clinicopathologic presentations of patients diagnosed with thyroid lymphomas at a tertiary cancer center. Thyroid lymphomas represent less than 2% of all lymphomas.
Methods
The lymphoma clinic database was retrospectively reviewed to collect information on patients diagnosed with thyroid lymphomas. Tissue microarrays were constructed in 37 patients for evaluation of germinal center (CD10/bcl‐6) and activated B‐cell immunophenotype markers (FoxP1, Mum1).
Results
During 2000 to 2010, 64 of 5668 patients registered at our lymphoma clinic were diagnosed with thyroid lymphoma (1.7%). Complete response (CR) to treatment was seen in 80.7%. The germinal center immunophenotype and activated B‐cell immune phenotype did not influence the prognosis. FoxP1, however, was associated with poor treatment response and decreased survival.
Conclusions
Advanced International Prognostic Index (IPI) score and combined‐modality treatment emerged as significant prognostic factors for treatment response and overall survival. Immunophenotype expression of FoxP1 carries a poor prognosis in diffuse large B‐cell lymphoma as elsewhere. © 2012 Wiley Periodicals, Inc. Head Neck, 2013</description><subject>activated B-cell lymphoma</subject><subject>Adult</subject><subject>Age Factors</subject><subject>Aged</subject><subject>Biopsy, Fine-Needle</subject><subject>Chemoradiotherapy - methods</subject><subject>Databases, Factual</subject><subject>diffuse large B-cell lymphoma</subject><subject>Disease-Free Survival</subject><subject>extranodal lymphoma</subject><subject>Female</subject><subject>Forkhead Transcription Factors - genetics</subject><subject>Gene Expression Regulation, Neoplastic</subject><subject>germinal center B cell</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>International Prognostic Index</subject><subject>Kaplan-Meier Estimate</subject><subject>Lymphoma, Large B-Cell, Diffuse - genetics</subject><subject>Lymphoma, Large B-Cell, Diffuse - mortality</subject><subject>Lymphoma, Large B-Cell, Diffuse - pathology</subject><subject>Lymphoma, Large B-Cell, Diffuse - therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Prognosis</subject><subject>Repressor Proteins - genetics</subject><subject>Retrospective Studies</subject><subject>Risk Assessment</subject><subject>Sex Factors</subject><subject>Survival Analysis</subject><subject>Tertiary Care Centers</subject><subject>Thyroid Neoplasms - genetics</subject><subject>Thyroid Neoplasms - mortality</subject><subject>Thyroid Neoplasms - pathology</subject><subject>Thyroid Neoplasms - therapy</subject><subject>tissue microarray</subject><issn>1043-3074</issn><issn>1097-0347</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kUtv1DAUhS0EoqWw4A8gS2xgkdaPJLbZwXQ6BcpjAWJpOc414zaJg52ozb-v2-mwQGJ1j46-e6R7D0IvKTmmhLCTLbTHjCkmH6FDSpQoCC_F4ztd8oITUR6gZyldEkJ4XbKn6IAxXkta1YfoatX5wdswmmkbuvDbW5ymuV2wGVoc5smGHrI23ZJ8wsHhabvE4FvcLf24Db1J7_D6ZoToYbCAXQw9NniCOHkTF2xNdiO2MGTrOXriTJfgxcM8Qj_P1j9W58XFt83H1fuLwnJFZWErRamTbVVBQ1qhXNMqqSrinDDGgXWybARjlDjprGJ1a6ThFQNDasdkw_gRerPLHWP4M0OadO-Tha4zA4Q5acoEl4TQUmb09T_oZZhjPveeooqXFVeZerujbAwpRXB6jL7P92lK9F0DOjeg7xvI7KuHxLnps7sn9y_PwMkOuPYdLP9P0ufr031ksdvwaYKbvxsmXulacFHpX183-sun7x9OV2cb_ZnfAkrQoDM</recordid><startdate>201302</startdate><enddate>201302</enddate><creator>Katna, Rakesh</creator><creator>Shet, Tanuja</creator><creator>Sengar, Manju</creator><creator>Menon, Hari</creator><creator>Laskar, Siddharth</creator><creator>Prabhash, Kumar</creator><creator>D'Cruz, Anil</creator><creator>Nair, Reena</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201302</creationdate><title>Clinicopathologic study and outcome analysis of thyroid lymphomas: Experience from a tertiary cancer center</title><author>Katna, Rakesh ; Shet, Tanuja ; Sengar, Manju ; Menon, Hari ; Laskar, Siddharth ; Prabhash, Kumar ; D'Cruz, Anil ; Nair, Reena</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3918-c5911f8d55eb0d79fbd98950ff7aafecf84b72210f8fc926da8a352ea06f28b23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>activated B-cell lymphoma</topic><topic>Adult</topic><topic>Age Factors</topic><topic>Aged</topic><topic>Biopsy, Fine-Needle</topic><topic>Chemoradiotherapy - methods</topic><topic>Databases, Factual</topic><topic>diffuse large B-cell lymphoma</topic><topic>Disease-Free Survival</topic><topic>extranodal lymphoma</topic><topic>Female</topic><topic>Forkhead Transcription Factors - genetics</topic><topic>Gene Expression Regulation, Neoplastic</topic><topic>germinal center B cell</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>International Prognostic Index</topic><topic>Kaplan-Meier Estimate</topic><topic>Lymphoma, Large B-Cell, Diffuse - genetics</topic><topic>Lymphoma, Large B-Cell, Diffuse - mortality</topic><topic>Lymphoma, Large B-Cell, Diffuse - pathology</topic><topic>Lymphoma, Large B-Cell, Diffuse - therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Prognosis</topic><topic>Repressor Proteins - genetics</topic><topic>Retrospective Studies</topic><topic>Risk Assessment</topic><topic>Sex Factors</topic><topic>Survival Analysis</topic><topic>Tertiary Care Centers</topic><topic>Thyroid Neoplasms - genetics</topic><topic>Thyroid Neoplasms - mortality</topic><topic>Thyroid Neoplasms - pathology</topic><topic>Thyroid Neoplasms - therapy</topic><topic>tissue microarray</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Katna, Rakesh</creatorcontrib><creatorcontrib>Shet, Tanuja</creatorcontrib><creatorcontrib>Sengar, Manju</creatorcontrib><creatorcontrib>Menon, Hari</creatorcontrib><creatorcontrib>Laskar, Siddharth</creatorcontrib><creatorcontrib>Prabhash, Kumar</creatorcontrib><creatorcontrib>D'Cruz, Anil</creatorcontrib><creatorcontrib>Nair, Reena</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Head & neck</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Katna, Rakesh</au><au>Shet, Tanuja</au><au>Sengar, Manju</au><au>Menon, Hari</au><au>Laskar, Siddharth</au><au>Prabhash, Kumar</au><au>D'Cruz, Anil</au><au>Nair, Reena</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinicopathologic study and outcome analysis of thyroid lymphomas: Experience from a tertiary cancer center</atitle><jtitle>Head & neck</jtitle><addtitle>Head Neck</addtitle><date>2013-02</date><risdate>2013</risdate><volume>35</volume><issue>2</issue><spage>165</spage><epage>171</epage><pages>165-171</pages><issn>1043-3074</issn><eissn>1097-0347</eissn><coden>HEANEE</coden><abstract>Background
The aim of this study was to review clinicopathologic presentations of patients diagnosed with thyroid lymphomas at a tertiary cancer center. Thyroid lymphomas represent less than 2% of all lymphomas.
Methods
The lymphoma clinic database was retrospectively reviewed to collect information on patients diagnosed with thyroid lymphomas. Tissue microarrays were constructed in 37 patients for evaluation of germinal center (CD10/bcl‐6) and activated B‐cell immunophenotype markers (FoxP1, Mum1).
Results
During 2000 to 2010, 64 of 5668 patients registered at our lymphoma clinic were diagnosed with thyroid lymphoma (1.7%). Complete response (CR) to treatment was seen in 80.7%. The germinal center immunophenotype and activated B‐cell immune phenotype did not influence the prognosis. FoxP1, however, was associated with poor treatment response and decreased survival.
Conclusions
Advanced International Prognostic Index (IPI) score and combined‐modality treatment emerged as significant prognostic factors for treatment response and overall survival. Immunophenotype expression of FoxP1 carries a poor prognosis in diffuse large B‐cell lymphoma as elsewhere. © 2012 Wiley Periodicals, Inc. Head Neck, 2013</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>22368156</pmid><doi>10.1002/hed.22928</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1043-3074 |
| ispartof | Head & neck, 2013-02, Vol.35 (2), p.165-171 |
| issn | 1043-3074 1097-0347 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1273800148 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | activated B-cell lymphoma Adult Age Factors Aged Biopsy, Fine-Needle Chemoradiotherapy - methods Databases, Factual diffuse large B-cell lymphoma Disease-Free Survival extranodal lymphoma Female Forkhead Transcription Factors - genetics Gene Expression Regulation, Neoplastic germinal center B cell Humans Immunohistochemistry International Prognostic Index Kaplan-Meier Estimate Lymphoma, Large B-Cell, Diffuse - genetics Lymphoma, Large B-Cell, Diffuse - mortality Lymphoma, Large B-Cell, Diffuse - pathology Lymphoma, Large B-Cell, Diffuse - therapy Male Middle Aged Neoplasm Staging Prognosis Repressor Proteins - genetics Retrospective Studies Risk Assessment Sex Factors Survival Analysis Tertiary Care Centers Thyroid Neoplasms - genetics Thyroid Neoplasms - mortality Thyroid Neoplasms - pathology Thyroid Neoplasms - therapy tissue microarray |
| title | Clinicopathologic study and outcome analysis of thyroid lymphomas: Experience from a tertiary cancer center |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T19%3A14%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinicopathologic%20study%20and%20outcome%20analysis%20of%20thyroid%20lymphomas:%20Experience%20from%20a%20tertiary%20cancer%20center&rft.jtitle=Head%20&%20neck&rft.au=Katna,%20Rakesh&rft.date=2013-02&rft.volume=35&rft.issue=2&rft.spage=165&rft.epage=171&rft.pages=165-171&rft.issn=1043-3074&rft.eissn=1097-0347&rft.coden=HEANEE&rft_id=info:doi/10.1002/hed.22928&rft_dat=%3Cproquest_cross%3E1273800148%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1271934539&rft_id=info:pmid/22368156&rfr_iscdi=true |